Jingfang Pharmaceutical-B (02595): Pan-RAS inhibitor GFH276 pancreatic cancer combination therapy study completed. The first phase II trial phase of administration to enrolled patients in China and overseas will include three first-line combination treatment plans

Zhitongcaijing · 2d ago

According to Zhitong Finance App, Jingfang Pharmaceutical-B (02595) announced that the oral Pan-RAS inhibitor GFH276 has entered a Phase IB/II multi-center, open-label combination therapy study. It will be carried out at dozens of Chinese and Australian research centers. The first overseas enrolment patient recently completed administration at Monash Health in Australia. The first Chinese enrolled patient completed administration at Fudan University Oncology Hospital in the third quarter of this year. The study aims to evaluate the efficacy and safety of multiple combination therapies for RAS mutant pancreatic cancer and advanced solid tumors; the phase II trial phase will include three first-line pancreatic cancer treatment cohorts, namely GFH276 combined with cetuximab (EGFR monoclonal antibody), GFH276 combined with AG (standardized treatment plan), and GFH276 combined with mfolfirinox (standardized treatment plan).

The clinical trial of GFH276 as a single agent for treating solid tumors was completed in September 2025. The clinical development progress is in the first tier of pan-RAS inhibitors in China. According to this year's ESMO Annual Conference Breakthrough Research Summary (LBA), as of the data cutoff date, 72.6% of pancreatic duct adenocarcinoma (PDAC) patients received GFH276 as line 3 or above treatment, and no dose-limiting toxicity was observed at 40-160 mg QD dose levels (patients did not use prophylactic drugs); 61 PDAC patients (40-160 mg QD) with an overall objective remission rate (ORR) of 61 PDAC patients (40-160 mg QD) that can evaluate efficacy were 41.1%. Patient ORR was 43.1%. According to multi-tumor animal experimental data from this year's AACR annual conference poster, standard treatments such as GFH276 combined with EGFR monoclonal antibodies and chemotherapy showed remarkable synergy and better tumor suppression effects, providing a translational medicine basis for this clinical study.

Dr. Wang Yu, Chief Medical Officer of Jingfang, said, “Pan-RAS inhibitors have shown the potential of innovative targeted treatments to change the survival time of large indications in clinical studies of solid tumors such as pancreatic cancer with single agents and combination chemotherapy. Jingfang has successfully promoted a number of world-leading first-line combination therapy trials with KRAS G12C/G12D inhibitors. We will provide the most suitable treatment plan for patients with different RAS mutations based on our deep development experience on the RAS circuit and push more excellent innovative treatments to the front line.”

According to Frost & Sullivan data, about 30% of cancer patients worldwide develop RAS mutations in their bodies, and it is estimated that there will be more than 6 million new cases of RAS mutations every year from 2025 to 2032. Of these, nearly 90% of pancreatic cancer patients develop RAS mutations. At present, various RAS therapies have been marketed at home and abroad, and ongoing research projects with various molecular morphologies have entered the middle and late stages of clinical trials, so the growth of the RAS circuit is gradually becoming prominent, and the market space is huge. According to Delveinsight data, the 10-year compound growth rate (CAGR) for KRAS (RAS mutation largest type) inhibitors was 35%, and the peak sales forecast for pan-RAS inhibitors by overseas investment and research institutes climbed from US$230 million (GlobalData) at the end of 2024 to US$8.3 billion (Bloomberg) in 2026.